Anti-tumour effects of red blood cell membrane-camouflaged black phosphorous quantum dots combined with chemotherapy and anti-inflammatory therapy

References

• Shapira A, Livney YD, Broxterman HJ, et al. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat. 2011;14:150–163.
   PubMed Web of Science ®Google Scholar
• Hori S, Herrera A, Rossi JJ, et al. Current advances in aptamers for cancer diagnosis and therapy. Cancers. 2018;10:9.
   Web of Science ®Google Scholar
• Bairagi U, Mittal P, Singh J, et al. Preparation, characterization, and in vivo evaluation of nano formulations of ferulic acid in diabetic wound healing. Drug Dev Ind Pharm. 2018;44:1783–1796.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Wang K, Karin M. Tumor-elicited inflammation and colorectal cancer. Adv Cancer Res. 2015;128:173–196.
   PubMed Web of Science ®Google Scholar
• Landskron G, De la Fuente M, Thuwajit P, et al. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:1.
   Web of Science ®Google Scholar
• Qiao Y, He H, Jonsson P, et al. AP-1 is a key regulator of proinflammatory cytokine TNFalpha-mediated triple-negative breast cancer progression. J Biol Chem. 2016;291:5068–5079.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Liang CH, Shi F, et al. Cancer vaccines using supramolecular hydrogels of NSAID-modified peptides as adjuvants abolish tumorigenesis. Nanoscale. 2017;9:14058–14064.
   PubMed Web of Science ®Google Scholar
• Buondonno I, Gazzano E, Jean SR, et al. Mitochondria-targeted doxorubicin: a new therapeutic strategy against doxorubicin-resistant osteosarcoma. Mol Cancer Ther. 2016;15:2640–2652.
   PubMed Web of Science ®Google Scholar
• Chen CJ, Kono H, Golenbock D, et al. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med. 2007;13:851–856.
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Lin GH, Yan YJ, et al. Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells. Oncogene. 2018;37:3456–3470.
   PubMed Web of Science ®Google Scholar
• Kim J, Kim MB, Yun JG, et al. Protective effects of standardized Siegesbeckia glabrescens extract and its active compound kirenol against UVB-induced photoaging through inhibition of MAPK/NF-kappaB pathways. J Microbiol Biotechnol. 2017;27:242–250.
   PubMed Web of Science ®Google Scholar
• Yin JT, Wang PQ, Yin YY, et al. Optimization on biodistribution and antitumor activity of tripterine using polymeric nanoparticles through RES saturation. Drug Deliv. 2017;24:1891–1897.
   Web of Science ®Google Scholar
• Hu Y, Ke L, Chen H, et al. Natural material-decorated mesoporous silica nanoparticle container for multifunctional membrane-controlled targeted drug delivery. IJN. 2017;12:8411–8426.
   Web of Science ®Google Scholar
• Shao JX, Abdelghani M, Shen GZ, et al. Erythrocyte membrane modified janus polymeric motors for thrombus therapy. ACS Nano. 2018;12:4877–4885.
   PubMed Web of Science ®Google Scholar
• Parodi A, Quattrocchi N, van de Ven AL, et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol. 2013;8:61–68.
   PubMed Web of Science ®Google Scholar
• Fang RH, Hu CMJ, Luk BT, et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014;14:2181–2188.
   PubMed Web of Science ®Google Scholar
• Gao WW, Fang RH, Thamphiwatana S, et al. Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. Nano Lett. 2015;15:1403–1409.
   PubMed Web of Science ®Google Scholar
• Li RX, He YW, Zhang SY, et al. Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment. Acta Pharm Sin B. 2018;8:14–22.
   PubMed Web of Science ®Google Scholar
• Oldenborg PA, Zheleznyak A, Fang YF, et al. Role of CD47 as a marker of self on red blood cells. Science. 2000;288:2051–2054.
   PubMed Web of Science ®Google Scholar
• Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189–207.
   PubMedGoogle Scholar
• Li M, Liu Y, Chen J, et al. Platelet bio-nanobubbles as microvascular recanalization nanoformulation for acute ischemic stroke lesion theranostics. Theranostics. 2018;8:4870–4883.
   PubMed Web of Science ®Google Scholar
• Tao W, Zhu X, Yu X, et al. Black phosphorus nanosheets as a robust delivery platform for cancer theranostics. Adv Mater. 2017;29;1603276.
   Web of Science ®Google Scholar
• Chen WS, Ouyang J, Liu H, et al. Black phosphorus nanosheet-based drug delivery system for synergistic photodynamic/photothermal/chemotherapy of cancer. Adv Mater. 2017;29;1603864.
   Web of Science ®Google Scholar
• Li Y, Liu Z, Hou Y, et al. Multifunctional nanoplatform based on black phosphorus quantum dots for bioimaging and photodynamic/photothermal synergistic cancer therapy. ACS Appl Mater Interfaces. 2017;9:25098–25106.
   PubMed Web of Science ®Google Scholar
• Yang Y, He L, Liu Y, et al. Promising nanocarriers for PEDF gene targeting delivery to cervical cancer cells mediated by the over-expressing FRalpha. Sci Rep. 2016;6:32427.
   PubMed Web of Science ®Google Scholar
• Jiang JG, Chen CL, Card JW, et al. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res. 2005;65:4707–4715.
   PubMed Web of Science ®Google Scholar
• Luk BT, Fang RH, Hu CMJ, et al. Safe and immunocompatible nanocarriers cloaked in RBC membranes for drug delivery to treat solid tumors. Theranostics. 2016;6:1004–1011.
   PubMed Web of Science ®Google Scholar
• Kumari N, Dwarakanath BS, Das A, et al. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumor Biol. 2016;37:11553–11572.
   PubMed Web of Science ®Google Scholar
• Garcia-Aranda M, Perez-Ruiz E, Redondo M. Bcl-2 inhibition to overcome resistance to chemo- and immunotherapy. Int J Mol Sci. 2018;19:3950.
   Web of Science ®Google Scholar
• Liu ZQ, Ding Y, Ye N, et al. Direct activation of Bax protein for cancer therapy. Med Res Rev. 2016;36:313–341.
   PubMed Web of Science ®Google Scholar
• Zheng JH, Follis AV, Kriwacki RW, et al. Discoveries and controversies in BCL-2 protein-mediated apoptosis. FEBS J. 2016;283:2690–2700.
   PubMed Web of Science ®Google Scholar
• Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol. 2011;12:715–723.
   PubMed Web of Science ®Google Scholar
• Chen MF, Chen PT, Lu MS, et al. IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer. 2013;12:26.
   PubMed Web of Science ®Google Scholar
• Dash SK, Chattopadhyay S, Ghosh T, et al. Self-assembled betulinic acid protects doxorubicin induced apoptosis followed by reduction of ROS-TNF-alpha-caspase-3 activity. Biomed Pharmacother. 2015;72:144–157.
   PubMed Web of Science ®Google Scholar
• Zhang F, Duan S, Tsai Y, et al. Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancer. Cancer Sci. 2016;107:746–754.
   PubMed Web of Science ®Google Scholar
• Ishimoto T, Miyake K, Nandi T, et al. Activation of transforming growth factor beta 1 signaling in gastric cancer-associated fibroblasts increases their motility, via expression of rhomboid 5 homolog 2, and ability to induce invasiveness of gastric cancer cells. Gastroenterology. 2017;153:191–204.
   PubMed Web of Science ®Google Scholar
• Keeney JT, Miriyala S, Noel T, et al. Superoxide induces protein oxidation in plasma and TNF-alpha elevation in macrophage culture: insights into mechanisms of neurotoxicity following doxorubicin chemotherapy. Cancer Lett. 2015;367:157–161.
   PubMed Web of Science ®Google Scholar
• Wei LH, Kuo ML, Chen CA, et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 2003;22:1517–1527.
   PubMed Web of Science ®Google Scholar
• Szwed M, Jozwiak Z. Genotoxic effect of doxorubicin-transferrin conjugate on human leukemia cells. Mutat Res Genet Toxicol Environ Mutagen. 2014;1;771:53–63.
   Web of Science ®Google Scholar
• Abushouk AI, Ismail A, Salem AMA, et al. Cardioprotective mechanisms of phytochemicals against doxorubicin-induced cardiotoxicity. Biomed Pharmacother. 2017;90:935–946.
   PubMed Web of Science ®Google Scholar